MyFinsight
Home
Blog
About
Contact
Proceeds from maturities
of marketable...
$73,950K
Payment of issuance
costs associated with...
-$70K
Proceeds from exercise of
stock options
$3K
Proceeds from issuance of
pre-funded warrants
$1K
Net cash used in
investing activities
$23,638K
Net cash provided by
financing activities
$74K
Canceled cashflow
$50,312K
Net decrease in cash
and cash...
-$6,786K
Canceled cashflow
$23,712K
Share-based compensation
expense
$4,145K
Investment tax credit
receivable
-$375K
Non-cash lease expense
-$243K
Depreciation of property and
equipment
$180K
Loss on impairment of
assets
$147K
Non-cash interest
expense
$136K
Purchases of marketable
securities
$50,214K
Purchases of property and
equipment
$98K
Net cash used in
operating activities
-$30,498K
Canceled cashflow
$5,226K
Net loss
-$30,227K
Accrued expenses and
other current...
-$2,485K
Prepaid expenses and
other assets
$1,582K
Accounts payable
-$625K
Accretion of marketable
securities
$494K
Lease liabilities
-$282K
Unrealized foreign
currency losses
$29K
Back
Back
Cash Flow
enGene Therapeutics Inc. (ENGNW)
enGene Therapeutics Inc. (ENGNW)
source: myfinsight.com